抗磷脂抗体相关不良产科结局孕妇妊娠期出血与抗血栓治疗:EUROAPS注册研究1075例调查
基于EUROAPS注册的多中心观察性研究,评估低剂量阿司匹林联合中高预防剂量低分子肝素在完全性及非标准产科抗磷脂综合征孕妇中的止血安全性,共1075例有抗血栓相关并发症数据。总体出血并发症4.93%(53例),轻微3.16%、严重1.76%;器械阴道分娩与剖宫产与局部出血相关,椎管内麻醉者无出血并发症,加用羟氯喹者无出血。
要点
- 妊娠期低剂量阿司匹林联合中高预防剂量低分子肝素在产科抗磷脂综合征中出血风险低。
- 器械阴道分娩和剖宫产与局部出血相关,需关注手术/器械分娩止血。
- 椎管内麻醉未观察到出血并发症,加用羟氯喹者无出血。
核心结论
- 低剂量阿司匹林联合中高预防剂量低分子肝素在完全性产科抗磷脂综合征及非标准产科抗磷脂综合征孕妇中安全。
- 器械分娩出血风险轻度增加,椎管内麻醉未发生出血并发症,加用羟氯喹者无出血。
研究设计与样本
- 回顾/前瞻性多中心观察性研究,来自30家欧洲三级医院。
- 研究1650例孕妇,其中1000例符合悉尼标准产科抗磷脂综合征、650例不符合;1075例(65.15%)有抗血栓相关并发症数据。
主要发现
- 总体出血并发症53例(4.93%),轻微34例(3.16%),严重19例(1.76%)。
- 产科并发症及实验室分类与出血无关。
- 器械阴道分娩和剖宫产与局部出血相关。
- 肝素剂量及血小板计数与严重出血无关。
- 椎管内麻醉者无出血并发症,加用羟氯喹者无出血。
关键数值与推荐
- 完全性产科抗磷脂综合征采用悉尼标准。
- 抗血栓方案为低剂量阿司匹林联合低分子肝素(中高预防剂量)至妊娠结束;难治性病例可加用羟氯喹。
临床怎么用
- 产科抗磷脂综合征孕妇可继续低剂量阿司匹林联合中高预防剂量低分子肝素,出血风险总体低。
- 器械阴道分娩或剖宫产时注意局部止血。
- 椎管内麻醉前按常规评估凝血,本研究未观察到椎管内麻醉出血并发症。
局限性
- 观察性研究设计。
- 仅65.15%病例有抗血栓相关并发症数据。
- 以白人/雅利安孕妇为主,其他族裔极少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The combination of low-dose aspirin (LDA) and low-molecular-weight heparin (LMWH) until the end of gestation are the currently the accepted standard of care for the treatment of antiphospholipid-related obstetric disorders. In refractory cases, hydroxychloroquine (HCQ) can be added to this standard of care. OBJECTIVE: To evaluate the haemostatic safety of LDA and LMWH (medium to high prophylactic doses) during pregnancy and the puerperium in women with both full-blown obstetric antiphospholipid syndrome (OAPS) (Sydney criteria) and noncriteria - incomplete - OAPS. STUDY DESIGN: Retrospective/prospective multicentre observational study. Obstetric background, laboratory categories, delivery mode, antithrombotic regimens and bleeding complications were compared. SETTING: A total of 30 tertiary European hospitals. PATIENTS: Mainly, Caucasian/Arian pregnant women were included. Other ethnicities were minimally present. Women were controlled throughout pregnancy and puerperium. MAIN OUTCOME MEASURES: The primary end-point was to evaluate the number of major and minor haemorrhagic complications in this cohort of women. Neuraxial anaesthetic bleeding complications were particularly assessed. Secondly, we aimed to compare local/general bleeding events between groups. RESULTS: We studied 1650 women, of whom 1000 fulfilled the Sydney criteria of the OAPS and 650 did not (noncriteria OAPS). Data on antithrombotic-related complications were available in 1075 cases (65.15%). Overall, 53 (4.93%) women had bleeding complications, with 34 being considered minor (3.16%) and 19 major (1.76%). Neither obstetric complications nor laboratory categories were bleeding-related. Assisted vaginal delivery and caesarean section were related to local haemorrhage. Heparin doses and platelet count were not associated with major bleeding. CONCLUSIONS: LDA and medium to high prophylactic LMWH during pregnancy in women with full-blown OAPS/noncriteria OAPS are safe. A slight increase in bleeding risk was noted in instrumental deliveries. No women who underwent spinal or epidural anaesthesia suffered bleeding complications. No haemorrhage was observed in cases where HCQ was added to standard therapy.
引用
- Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, et al. Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes: A survey of 1075 cases from EUROAPS registry∗. Eur J Anaesthesiol. 2021. PMID: 34397526. doi:10.1097/EJA.0000000000001484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。